Laplante P, Rosa R, Nebot-Bral L, Goulas J, Pouvelle C, Nikolaev S
Neoplasia. 2025; 62:101145.
PMID: 39985912
PMC: 11905862.
DOI: 10.1016/j.neo.2025.101145.
Chakraborty S, Banerjee S
Mol Biol Rep. 2023; 50(11):9601-9623.
PMID: 37792172
DOI: 10.1007/s11033-023-08852-0.
Kim Y, Park H, Kim H, Park S
J Korean Med Sci. 2023; 38(21):e163.
PMID: 37270918
PMC: 10226847.
DOI: 10.3346/jkms.2023.38.e163.
Patysheva M, Frolova A, Larionova I, Afanasev S, Tarasova A, Cherdyntseva N
Front Immunol. 2022; 13:994319.
PMID: 36341366
PMC: 9631446.
DOI: 10.3389/fimmu.2022.994319.
Silveira C, Corveloni A, Caruso S, Macedo N, Brussolo N, Haddad F
Front Immunol. 2022; 13:947648.
PMID: 36172343
PMC: 9512053.
DOI: 10.3389/fimmu.2022.947648.
Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors.
Matsui J, Perlow H, Raj R, Nalin A, Lehrer E, Kotecha R
Biomedicines. 2022; 10(9).
PMID: 36140312
PMC: 9496359.
DOI: 10.3390/biomedicines10092211.
A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer.
Kim S, Kim B, Kim I, Kim J, Kim H, Ryu H
J Cancer. 2022; 13(4):1363-1369.
PMID: 35281880
PMC: 8899359.
DOI: 10.7150/jca.70385.
VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment.
Zhang Y, Huang H, Coleman M, Ziemys A, Gopal P, Kazmi S
JCI Insight. 2021; 6(23).
PMID: 34673569
PMC: 8675197.
DOI: 10.1172/jci.insight.150735.
Prognostic significance of the postoperative prognostic nutritional index in patients with glioblastoma: a retrospective study.
Kim Y, Oh H, Lee S, Kim K, Kang H, Park C
BMC Cancer. 2021; 21(1):942.
PMID: 34418999
PMC: 8380354.
DOI: 10.1186/s12885-021-08686-8.
Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action.
Palte R, Juan V, Gomez-Llorente Y, Bailly M, Chakravarthy K, Chen X
Commun Biol. 2021; 4(1):927.
PMID: 34326456
PMC: 8322407.
DOI: 10.1038/s42003-021-02444-z.
Identification and characterization of B220/B220 subpopulations in murine Gr1CD11b cells during tumorigenesis.
Zhang Z, Huang X, Wang E, Huang Y, Yang R
Oncoimmunology. 2021; 10(1):1912472.
PMID: 33948392
PMC: 8057082.
DOI: 10.1080/2162402X.2021.1912472.
Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade.
Zhao X, Shao C
Cancers (Basel). 2020; 12(10).
PMID: 32992835
PMC: 7600068.
DOI: 10.3390/cancers12102762.
miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells.
Zhang X, Li F, Tang Y, Ren Q, Xiao B, Wan Y
Oncogene. 2020; 39(40):6354-6369.
PMID: 32855524
DOI: 10.1038/s41388-020-01406-9.
Tumor Excision as a Metastatic Russian Roulette: Perioperative Interventions to Improve Long-Term Survival of Cancer Patients.
Ben-Eliyahu S
Trends Cancer. 2020; 6(11):951-959.
PMID: 32654993
PMC: 9385467.
DOI: 10.1016/j.trecan.2020.06.004.
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A, Hou K, Huang Q, Lei Y, Chen W
Front Immunol. 2020; 11:783.
PMID: 32508809
PMC: 7249937.
DOI: 10.3389/fimmu.2020.00783.
Circulating and tumor-infiltrating arginase 1-expressing cells in gastric adenocarcinoma patients were mainly immature and monocytic Myeloid-derived suppressor cells.
Ren W, Zhang X, Li W, Feng Q, Feng H, Tong Y
Sci Rep. 2020; 10(1):8056.
PMID: 32415175
PMC: 7229115.
DOI: 10.1038/s41598-020-64841-4.
Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance.
Khan S, Mittal S, McGee K, Alfaro-Munoz K, Majd N, Balasubramaniyan V
Int J Mol Sci. 2020; 21(6).
PMID: 32182988
PMC: 7139844.
DOI: 10.3390/ijms21061954.
Neutrophils as Suppressors of T Cell Proliferation: Does Age Matter?.
Aarts C, Hiemstra I, Tool A, van den Berg T, Mul E, van Bruggen R
Front Immunol. 2019; 10:2144.
PMID: 31572368
PMC: 6749034.
DOI: 10.3389/fimmu.2019.02144.
GM-CSF Promotes the Expansion and Differentiation of Cord Blood Myeloid-Derived Suppressor Cells, Which Attenuate Xenogeneic Graft-vs.-Host Disease.
Park M, Lim B, Kim S, Sohn H, Kim S, Kim T
Front Immunol. 2019; 10:183.
PMID: 30863394
PMC: 6399310.
DOI: 10.3389/fimmu.2019.00183.
Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment.
Sceneay J, Griessinger C, Hoffmann S, Wen S, Wong C, Krumeich S
PLoS One. 2018; 13(4):e0196040.
PMID: 29677215
PMC: 5909918.
DOI: 10.1371/journal.pone.0196040.
